Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B

BACKGROUND: Previous studies have revealed that hepatitis B core antibody (anti-HBc) levels vary throughout the different phases of treatment-naïve chronic hepatitis B (CHB) patients and can be used as a predictor of treatment response in both interferon-α and nucleoside analogue therapies. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Min-ran, Zheng, Huan-wei, Lu, Jian-hua, Ma, Shun-mao, Ye, Li-hong, Liu, Zhi-quan, Zhang, Hai-cong, Liu, Yun-yan, Lv, Ying, Huang, Yan, Dai, Er-hei, Sun, Dian-xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355246/
https://www.ncbi.nlm.nih.gov/pubmed/28052021
http://dx.doi.org/10.18632/oncotarget.14323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355246/
https://www.ncbi.nlm.nih.gov/pubmed/28052021
http://dx.doi.org/10.18632/oncotarget.14323

Ejemplares similares